164 related articles for article (PubMed ID: 36444905)
21. Omaveloxolone: potential new agent for Friedreich ataxia.
Lynch DR; Johnson J
Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
[TBL] [Abstract][Full Text] [Related]
22. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.
Reetz K; Dogan I; Hilgers RD; Giunti P; Mariotti C; Durr A; Boesch S; Klopstock T; de Rivera FJR; Schöls L; Klockgether T; Bürk K; Rai M; Pandolfo M; Schulz JB;
Lancet Neurol; 2016 Dec; 15(13):1346-1354. PubMed ID: 27839651
[TBL] [Abstract][Full Text] [Related]
23. Friedreich's ataxia: idebenone treatment in early stage patients.
Artuch R; Aracil A; Mas A; Colomé C; Rissech M; Monrós E; Pineda M
Neuropediatrics; 2002 Aug; 33(4):190-3. PubMed ID: 12368988
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial.
Madsen KL; Buch AE; Cohen BH; Falk MJ; Goldsberry A; Goldstein A; Karaa A; Koenig MK; Muraresku CC; Meyer C; O'Grady M; Scaglia F; Shieh PB; Vockley J; Zolkipli-Cunningham Z; Haller RG; Vissing J
Neurology; 2020 Feb; 94(7):e687-e698. PubMed ID: 31896620
[TBL] [Abstract][Full Text] [Related]
25. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia.
Filla A; De Michele G; Orefice G; Santorelli F; Trombetta L; Banfi S; Squitieri F; Napolitano G; Puma D; Campanella G
Can J Neurol Sci; 1993 Feb; 20(1):52-5. PubMed ID: 8467430
[TBL] [Abstract][Full Text] [Related]
26. Idebenone in Friedreich's ataxia.
Tonon C; Lodi R
Expert Opin Pharmacother; 2008 Sep; 9(13):2327-37. PubMed ID: 18710357
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
28. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.
Alfedi G; Luffarelli R; Condò I; Pedini G; Mannucci L; Massaro DS; Benini M; Toschi N; Alaimo G; Panarello L; Pacini L; Fortuni S; Serio D; Malisan F; Testi R; Rufini A
Mov Disord; 2019 Mar; 34(3):323-334. PubMed ID: 30624801
[TBL] [Abstract][Full Text] [Related]
29. Harmonizing results of ataxia rating scales: mFARS, SARA, and ICARS.
Rummey C; Harding IH; Delatycki MB; Tai G; Rezende T; Corben LA
Ann Clin Transl Neurol; 2022 Dec; 9(12):2041-2046. PubMed ID: 36394163
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Biomarkers in Friedreich's Ataxia: a Systematic Review and Meta-analysis.
Gavriilaki M; Chatzikyriakou E; Moschou M; Arnaoutoglou M; Sakellari I; Kimiskidis VK
Cerebellum; 2024 Jun; 23(3):1184-1203. PubMed ID: 37889470
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia.
Boesch S; Nachbauer W; Mariotti C; Sacca F; Filla A; Klockgether T; Klopstock T; Schöls L; Jacobi H; Büchner B; vom Hagen JM; Nanetti L; Manicom K
Mov Disord; 2014 Jun; 29(7):935-9. PubMed ID: 24515352
[TBL] [Abstract][Full Text] [Related]
32. Delayed-onset Friedreich's ataxia revisited.
Lecocq C; Charles P; Azulay JP; Meissner W; Rai M; N'Guyen K; Péréon Y; Fabre N; Robin E; Courtois S; Guyant-Maréchal L; Zagnoli F; Rudolf G; Renaud M; Sévin-Allouet M; Lesne F; Alaerts N; Goizet C; Calvas P; Eusebio A; Guissart C; Derkinderen P; Tison F; Brice A; Koenig M; Pandolfo M; Tranchant C; Dürr A; Anheim M
Mov Disord; 2016 Jan; 31(1):62-9. PubMed ID: 26388117
[TBL] [Abstract][Full Text] [Related]
33. Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.
Ghanekar SD; Miller WW; Meyer CJ; Fenelon KJ; Lacdao A; Zesiewicz TA
Degener Neurol Neuromuscul Dis; 2019; 9():103-107. PubMed ID: 31686946
[TBL] [Abstract][Full Text] [Related]
34. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.
Subramony SH; Lynch DL
Cerebellum; 2024 Apr; 23(2):775-777. PubMed ID: 37219716
[TBL] [Abstract][Full Text] [Related]
35. Digital endpoints for self-administered home-based functional assessment in pediatric Friedreich's ataxia.
Mueller A; Paterson E; McIntosh A; Praestgaard J; Bylo M; Hoefling H; Wells M; Lynch DR; Rummey C; Krishnan ML; Schultz M; Malanga CJ
Ann Clin Transl Neurol; 2021 Sep; 8(9):1845-1856. PubMed ID: 34355532
[TBL] [Abstract][Full Text] [Related]
36. Nerve ultrasound in Friedreich's Ataxia: enlarged nerves as a biomarker of disease severity.
Di Pietro G; Cioffi E; Falco P; Galosi E; De Stefano G; Di Stefano G; Leone C; Martines V; Perotti S; Casali C; Truini A
Clin Neurophysiol; 2024 Mar; 159():75-80. PubMed ID: 38359552
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Survival in Friedreich's Ataxia: A Prospective Cohort Study.
Indelicato E; Reetz K; Maier S; Nachbauer W; Amprosi M; Giunti P; Mariotti C; Durr A; de Rivera Garrido FJR; Klopstock T; Schöls L; Klockgether T; Bürk K; Pandolfo M; Didszun C; Grobe-Einsler M; Nanetti L; Nenning L; Kiechl S; Dichtl W; Ulmer H; Schulz JB; Boesch S;
Mov Disord; 2024 Mar; 39(3):510-518. PubMed ID: 38140802
[TBL] [Abstract][Full Text] [Related]
38. Characterizing cardiac phenotype in Friedreich's ataxia: The CARFA study.
Legrand L; Weinsaft JW; Pousset F; Ewenczyk C; Charles P; Hatem S; Heinzmann A; Biet M; Durr A; Redheuil A
Arch Cardiovasc Dis; 2022 Jan; 115(1):17-28. PubMed ID: 34920960
[TBL] [Abstract][Full Text] [Related]
39. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.
Velasco-Sánchez D; Aracil A; Montero R; Mas A; Jiménez L; O'Callaghan M; Tondo M; Capdevila A; Blanch J; Artuch R; Pineda M
Cerebellum; 2011 Mar; 10(1):1-8. PubMed ID: 20865357
[TBL] [Abstract][Full Text] [Related]
40. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
Profeta V; McIntyre K; Wells M; Park C; Lynch DR
Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
